Literature DB >> 18332877

Family-based association testing strongly implicates DRD2 as a risk gene for schizophrenia in Han Chinese from Taiwan.

S J Glatt1, S V Faraone, J A Lasky-Su, T Kanazawa, H-G Hwu, M T Tsuang.   

Abstract

The gene that codes for dopamine receptor D2 (DRD2 on chromosome 11q23) has long been a prime functional and positional candidate risk gene for schizophrenia. Collectively, prior case-control studies found a reliable effect of the Ser311Cys DRD2 polymorphism (rs1801028) on risk for schizophrenia, but few other polymorphisms in the gene had ever been evaluated and no adequately powered family-based association study has been performed to date. Our objective was to test 21 haplotype-tagging and all three known nonsynonymous single-nucleotide polymorphisms (SNPs) in DRD2 for association with schizophrenia in a family-based study of 2408 Han Chinese, including 1214 affected individuals from 616 families. We did not find a significant effect of rs1801028, but we did find significant evidence for association of schizophrenia with two multi-marker haplotypes spanning blocks of strong linkage disequilibrium (LD) and nine individual SNPs (Ps<0.05). Importantly, two SNPs (rs1079727 and rs2283265) and both multi-marker haplotypes spanning entire LD blocks (including one that contained rs1801028) remained significant after correcting for multiple testing. These results further add to the body of data implicating DRD2 as a schizophrenia risk gene; however, a causal variant(s) in DRD2 remains to be elucidated by further fine mapping of the gene, with particular attention given to the area surrounding the third through fifth exons.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18332877      PMCID: PMC2755547          DOI: 10.1038/mp.2008.30

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  29 in total

1.  PBAT: tools for family-based association studies.

Authors:  Christoph Lange; Dawn DeMeo; Edwin K Silverman; Scott T Weiss; Nan M Laird
Journal:  Am J Hum Genet       Date:  2004-02       Impact factor: 11.025

2.  The International HapMap Project.

Authors: 
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

3.  A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other.

Authors:  Dale R Nyholt
Journal:  Am J Hum Genet       Date:  2004-03-02       Impact factor: 11.025

4.  The effect of family structure on linkage tests using allelic association.

Authors:  J C Whittaker; C M Lewis
Journal:  Am J Hum Genet       Date:  1998-09       Impact factor: 11.025

5.  No association of the Ser/Cys311 DRD2 molecular variant with schizophrenia using a classical case control study and the haplotype relative risk.

Authors:  M Verga; F Macciardi; S Pedrini; S Cohen; E Smeraldi
Journal:  Schizophr Res       Date:  1997-05-24       Impact factor: 4.939

6.  Meta-analysis identifies an association between the dopamine D2 receptor gene and schizophrenia.

Authors:  S J Glatt; S V Faraone; M T Tsuang
Journal:  Mol Psychiatry       Date:  2003-11       Impact factor: 15.992

7.  Functional analysis of the human D2 dopamine receptor missense variants.

Authors:  A Cravchik; D R Sibley; P V Gejman
Journal:  J Biol Chem       Date:  1996-10-18       Impact factor: 5.157

8.  Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative.

Authors:  J I Nurnberger; M C Blehar; C A Kaufmann; C York-Cooler; S G Simpson; J Harkavy-Friedman; J B Severe; D Malaspina; T Reich
Journal:  Arch Gen Psychiatry       Date:  1994-11

9.  A structural polymorphism of human dopamine D2 receptor, D2(Ser311-->Cys).

Authors:  M Itokawa; T Arinami; N Futamura; H Hamaguchi; M Toru
Journal:  Biochem Biophys Res Commun       Date:  1993-11-15       Impact factor: 3.575

10.  Association of dopamine D2 receptor molecular variant with schizophrenia.

Authors:  T Arinami; M Itokawa; H Enguchi; H Tagaya; S Yano; H Shimizu; H Hamaguchi; M Toru
Journal:  Lancet       Date:  1994-03-19       Impact factor: 79.321

View more
  24 in total

Review 1.  Genetic neuropathology of schizophrenia: new approaches to an old question and new uses for postmortem human brains.

Authors:  Joel E Kleinman; Amanda J Law; Barbara K Lipska; Thomas M Hyde; Justin K Ellis; Paul J Harrison; Daniel R Weinberger
Journal:  Biol Psychiatry       Date:  2011-01-15       Impact factor: 13.382

Review 2.  Co-shared genetics and possible risk gene pathway partially explain the comorbidity of schizophrenia, major depressive disorder, type 2 diabetes, and metabolic syndrome.

Authors:  Teodor T Postolache; Laura Del Bosque-Plata; Serge Jabbour; Michael Vergare; Rongling Wu; Claudia Gragnoli
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2019-02-06       Impact factor: 3.568

3.  Impact of COMT Val158Met on executive functioning in the context of HIV and methamphetamine.

Authors:  Chad A Bousman; Mariana Cherner; Stephen J Glatt; J Hampton Atkinson; Igor Grant; Ming T Tsuang; Ian P Everall
Journal:  Neurobehav HIV Med       Date:  2010-01-01

4.  Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions.

Authors:  Yunlong Ma; Wenji Yuan; Xianzhong Jiang; Wen-Yan Cui; Ming D Li
Journal:  Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.590

5.  Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse.

Authors:  Robert A Moyer; Danxin Wang; Audrey C Papp; Ryan M Smith; Linda Duque; Deborah C Mash; Wolfgang Sadee
Journal:  Neuropsychopharmacology       Date:  2010-12-08       Impact factor: 7.853

6.  Similarities and differences in peripheral blood gene-expression signatures of individuals with schizophrenia and their first-degree biological relatives.

Authors:  Stephen J Glatt; William S Stone; Nadine Nossova; Choong-Chin Liew; Larry J Seidman; Ming T Tsuang
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2011-10-03       Impact factor: 3.568

7.  Contrasting changes in DRD1 and DRD2 splice variant expression in schizophrenia and affective disorders, and associations with SNPs in postmortem brain.

Authors:  S S Kaalund; E N Newburn; T Ye; R Tao; C Li; A Deep-Soboslay; M M Herman; T M Hyde; D R Weinberger; B K Lipska; J E Kleinman
Journal:  Mol Psychiatry       Date:  2013-12-10       Impact factor: 15.992

8.  A variant in ANKK1 modulates acute subjective effects of cocaine: a preliminary study.

Authors:  C J Spellicy; M J Harding; S C Hamon; J J Mahoney; J A Reyes; T R Kosten; T F Newton; R De La Garza; D A Nielsen
Journal:  Genes Brain Behav       Date:  2014-03-17       Impact factor: 3.449

9.  Functional variants of the dopamine receptor D2 gene modulate prefronto-striatal phenotypes in schizophrenia.

Authors:  Alessandro Bertolino; Leonardo Fazio; Grazia Caforio; Giuseppe Blasi; Antonio Rampino; Raffaella Romano; Annabella Di Giorgio; Paolo Taurisano; Audrey Papp; Julia Pinsonneault; Danxin Wang; Marcello Nardini; Teresa Popolizio; Wolfgang Sadee
Journal:  Brain       Date:  2008-10-01       Impact factor: 13.501

10.  Genetically determined measures of striatal D2 signaling predict prefrontal activity during working memory performance.

Authors:  Alessandro Bertolino; Paolo Taurisano; Nicola Marco Pisciotta; Giuseppe Blasi; Leonardo Fazio; Raffaella Romano; Barbara Gelao; Luciana Lo Bianco; Madia Lozupone; Annabella Di Giorgio; Grazia Caforio; Fabio Sambataro; Artor Niccoli-Asabella; Audrey Papp; Gianluca Ursini; Lorenzo Sinibaldi; Teresa Popolizio; Wolfgang Sadee; Giuseppe Rubini
Journal:  PLoS One       Date:  2010-02-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.